{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:42:47Z","timestamp":1792806167584,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Astellas"},{"name":"Bayer Hispania S.L."},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04446-x","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T18:18:38Z","timestamp":1780683518000},"page":"5031-5054","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical advances and practice updates in genitourinary cancers: a 2025 review from the multidisciplinary Spanish \u2018Cambados annual meeting\u2019"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4973-3198","authenticated-orcid":false,"given":"Sergio","family":"V\u00e1zquez-Est\u00e9vez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"L\u00e1zaro-Quintela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"P\u00e9rez-Fentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Esteban-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"\u00c1lvarez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urbano","family":"Anido-Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Azpitarte Raposeiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Casas-Nebra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidio","family":"Fern\u00e1ndez Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Fern\u00e1ndez N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Folgar-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Garc\u00eda Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ar\u00e1nzazu","family":"Gonz\u00e1lez-del-Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"M\u00e9ndez-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurea","family":"Molina D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Rodr\u00edguez G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"P. Valderrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Pel\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"3","key":"4446_CR1","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jncc.2025.03.001","volume":"5","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Xie Y, Liu L, Wang Y, Li S, Chen L, et al. Global, regional, and national burden of genitourinary cancers in 204 countries and territories, 1990-2021: a systematic analysis for the global burden of disease study 2021. J Natl Cancer Cent. 2025;5(3):330\u201345. https:\/\/doi.org\/10.1016\/j.jncc.2025.03.001.","journal-title":"J Natl Cancer Cent"},{"issue":"17","key":"4446_CR2","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1002\/cncr.34907","volume":"129","author":"F Jackson-Spence","year":"2023","unstructured":"Jackson-Spence F, Young M, Sweeney C, Powles T. Top advances of the year: genitourinary cancer. Cancer. 2023;129(17):2603\u20139. https:\/\/doi.org\/10.1002\/cncr.34907.","journal-title":"Cancer"},{"issue":"8","key":"4446_CR3","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2967\/jnumed.125.269996","volume":"66","author":"AW Mogensen","year":"2025","unstructured":"Mogensen AW, Torp-Pedersen C, Norgaard M, Petersen LJ, Moe M, Zacho HD. The use of PSMA PET\/CT improves overall survival in men with biochemically recurrent prostate cancer treated with salvage radiotherapy: real-world data from an entire country. J Nucl Med. 2025;66(8):1217\u201322. https:\/\/doi.org\/10.2967\/jnumed.125.269996.","journal-title":"J Nucl Med"},{"issue":"3","key":"4446_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.eururo.2025.05.013","volume":"88","author":"S Burdett","year":"2025","unstructured":"Burdett S, Fisher DJ, Tierney JF, Cook AD, Spratt DE, Dignam JJ, et al. Duration of androgen suppression with postoperative radiotherapy (DADSPORT) for non-metastatic prostate cancer: a collaborative systematic review and meta-analysis of aggregate data. Eur Urol. 2025;88(3):277\u201390. https:\/\/doi.org\/10.1016\/j.eururo.2025.05.013.","journal-title":"Eur Urol"},{"key":"4446_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510310","author":"ND Shore","year":"2025","unstructured":"Shore ND, Luz MA, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved survival with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2510310. (Online ahead of print).","journal-title":"N Engl J Med"},{"issue":"6","key":"4446_CR6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","volume":"26","author":"P Ost","year":"2025","unstructured":"Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte FX, et al. Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial. Lancet Oncol. 2025;26(6):695\u2013706. https:\/\/doi.org\/10.1016\/S1470-2045(25)00197-4.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4446_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1702900.","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"4446_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5001","volume":"43","author":"CTA Parker","year":"2025","unstructured":"Parker CTA, Liu VY, Mendes L, Grist E, Yamashita R, Croucher DC, et al. Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE. J Clin Oncol. 2025;43(16_suppl):5001-. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.5001.","journal-title":"J Clin Oncol"},{"key":"4446_CR9","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO.24.00418","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad F, Vjaters E, Shore N, Olmos D, Xing N, Gomes AJPdS, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42:4271\u201381. https:\/\/doi.org\/10.1200\/JCO.24.00418.","journal-title":"J Clin Oncol"},{"key":"4446_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03961-8","author":"G Attard","year":"2025","unstructured":"Attard G, Agarwal N, Graff JN, Sandhu S, Efstathiou E, Ozguroglu M, et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03961-8.","journal-title":"Nat Med"},{"issue":"25","key":"4446_CR11","doi-asserted-by":"publisher","first-page":"04936","DOI":"10.1016\/j.annonc.2025.10.004","volume":"S0923\u20137534","author":"K Fizazi","year":"2025","unstructured":"Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2025;S0923\u20137534(25):04936\u201341. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.004.","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"4446_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5003","volume":"43","author":"E Grist","year":"2025","unstructured":"Grist E, Dutey-Magni P, Parry M, Mendes L, Sachdeva A, Proudfoot JA, et al. Transcriptome classification of PTEN inactivation to predict survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for metastatic prostate cancer (PC): an ancillary study of the STAMPEDE trials. J Clin Oncol. 2025;43(16_suppl):5003-. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.5003.","journal-title":"J Clin Oncol"},{"key":"4446_CR13","doi-asserted-by":"publisher","first-page":"S1742","DOI":"10.1016\/j.annonc.2025.09.101","volume":"Suppl 2","author":"ST Tagawa","year":"2025","unstructured":"Tagawa ST, Sartor O, Piulats JM, Saad F, Fizazi K, Reid AH, et al. LBA6 - phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). Ann Oncol. 2025;Suppl 2:S1742\u20133. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.101.","journal-title":"Ann Oncol"},{"issue":"10","key":"4446_CR14","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00551-2","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(10):1094\u2013108. https:\/\/doi.org\/10.1016\/S1470-2045(23)00551-2.","journal-title":"Lancet Oncol"},{"issue":"5_suppl","key":"4446_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.219","volume":"43","author":"F Saad","year":"2025","unstructured":"Saad F, Armstrong AJ, Oya M, Shore ND, Arslan C, Vianna KCM, et al. Efficacy of olaparib (ola) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with a germline or somatic BRCA mutation in the PROpel trial. J Clin Oncol. 2025;43(5_suppl):219-. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.219.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4446_CR16","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.euo.2025.04.012","volume":"8","author":"KN Chi","year":"2025","unstructured":"Chi KN, Castro E, Attard G, Smith MR, Sandhu S, Efstathiou E, et al. Niraparib and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: final overall survival analysis for the phase 3 MAGNITUDE trial. Eur Urol Oncol. 2025;8(4):986\u201398. https:\/\/doi.org\/10.1016\/j.euo.2025.04.012.","journal-title":"Eur Urol Oncol"},{"issue":"10502","key":"4446_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","volume":"406","author":"K Fizazi","year":"2025","unstructured":"Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, et al. Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025;406(10502):461\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(25)00683-X.","journal-title":"Lancet"},{"issue":"10502","key":"4446_CR18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","volume":"406","author":"N Agarwal","year":"2025","unstructured":"Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, et al. Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025;406(10502):447\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(25)00684-1.","journal-title":"Lancet"},{"issue":"11","key":"4446_CR19","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.annonc.2025.07.003","volume":"36","author":"K Fizazi","year":"2025","unstructured":"Fizazi K, Chi KN, Shore ND, Herrmann K, de Bono JS, Castellano D, et al. Final overall survival and safety analyses of the phase III PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025;36(11):1319\u201330. https:\/\/doi.org\/10.1016\/j.annonc.2025.07.003.","journal-title":"Ann Oncol"},{"key":"4446_CR20","doi-asserted-by":"publisher","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2307","volume":"35","author":"S Gillessen","year":"2024","unstructured":"Gillessen S, Choudhury A, Saad F, Gallardo E, Soares A, Loriot Y, et al. LBA1 a randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): first results of EORTC-GUCG 1333\/PEACE-3. Ann Oncol. 2024;35:S1254. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2307.","journal-title":"Ann Oncol"},{"issue":"8","key":"4446_CR21","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1007\/s12094-025-03850-z","volume":"27","author":"I Pel\u00e1ez","year":"2025","unstructured":"Pel\u00e1ez I, L\u00e1zaro-Quintela M, P\u00e9rez-Fentes D, Esteban-Gonz\u00e1lez E, Gallardo E, \u00c1lvarez-Fern\u00e1ndez C, et al. Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish \u201cCambados annual meeting.\u201d Clin Transl Oncol. 2025;27(8):3307\u201324. https:\/\/doi.org\/10.1007\/s12094-025-03850-z.","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"4446_CR22","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.annonc.2025.05.011","volume":"36","author":"B Tombal","year":"2025","unstructured":"Tombal B, Choudhury A, Saad F, Gallardo E, Soares A, Loriot Y, et al. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial. Ann Oncol. 2025;36(9):1058\u201367. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.011.","journal-title":"Ann Oncol"},{"key":"4446_CR23","unstructured":"EORTC. Press release: EORTC announces final overall survival results from the PEACE-3 trial. 2025 cited. https:\/\/www.eortc.org\/blog\/2025\/10\/19\/eortc-announces-final-overall-survival-results-from-the-peace-3-trial\/. Accessed 09 Dec 2025."},{"issue":"14","key":"4446_CR24","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/jco-24-01283","volume":"43","author":"DP Petrylak","year":"2025","unstructured":"Petrylak DP, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, et al. Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial. J Clin Oncol. 2025;43(14):1638\u201349. https:\/\/doi.org\/10.1200\/jco-24-01283.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"4446_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4514","volume":"43","author":"NB Haas","year":"2025","unstructured":"Haas NB, Powles T, Tomczak P, Park SH, Venugopal B, Symeonides SN, et al. Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2025;43(16_suppl):4514-. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4514.","journal-title":"J Clin Oncol"},{"key":"4446_CR26","doi-asserted-by":"crossref","unstructured":"Larkin J, Powles TB, Frangou E, Stewart GD, Albiges L, Davis ID, et al. First results from RAMPART: an international phase III randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL [Abstract LBA95]. 2025. https:\/\/kidney.uroonco.uroweb.org\/publication\/first-results-from-rampart-an-international-phase-iii-randomised-controlled-trial-of-adjuvant-durvalumab-monotherapy-or-combined-with-tremelimumab-for-resected-primary-renal-cell-carcinoma-rcc-led\/. Accessed 09 Dec 2025.","DOI":"10.1016\/j.annonc.2025.09.110"},{"key":"4446_CR27","doi-asserted-by":"crossref","unstructured":"Burgers F, De Ruijter A, Graafland NM, Van Montfoort M, Lopez-Yurda M, Hagen Pea. Neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: the randomized phase II NESCIO trial. 2025. https:\/\/kidney.uroonco.uroweb.org\/publication\/neoadjuvant-immunotherapy-in-locally-advanced-clear-cell-renal-cell-carcinoma-at-risk-for-recurrence-or-distant-metastases-the-randomized-phase-ii-nescio-trial\/. Accessed 09 Dec 2025.","DOI":"10.1016\/j.annonc.2025.09.112"},{"issue":"16_suppl","key":"4446_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4509","volume":"43","author":"A Bex","year":"2025","unstructured":"Bex A, Mijn JCvd, Graafland N, Thienen JVv, Wilgenhof S, Lagerveld B, et al. Exploratory analysis from NEOAVAX, a neoadjuvant trial of avelumab\/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy. J Clin Oncol. 2025;43(16_suppl):4509-. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4509.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"4446_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4505","volume":"43","author":"TK Choueiri","year":"2025","unstructured":"Choueiri TK, Escudier B, McDermott DF, Burotto M, Hammers HJ, Plimack ER, et al. Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis from the phase 3 CheckMate 214 trial. J Clin Oncol. 2025;43(16_suppl):4505-. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4505.","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"4446_CR30","doi-asserted-by":"publisher","first-page":"439-","DOI":"10.1056\/NEJMoa1712126","volume":"43","author":"RJ Motzer","year":"2025","unstructured":"Motzer RJ, Escudier B, Burotto M, Powles T, Apolo AB, Bourlon MT, et al. Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): final follow-up results from the CheckMate 9ER trial. J Clin Oncol. 2025;43(5_suppl):439-. https:\/\/doi.org\/10.1056\/NEJMoa1712126.","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"4446_CR31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.438","volume":"43","author":"L Albiges","year":"2025","unstructured":"Albiges L, Motzer RJ, Trevino S, Kanesvaran R, Centkowski P, Reimers MA, et al. Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): final results of COSMIC-313. J Clin Oncol. 2025;43(5_suppl):438-. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.438.","journal-title":"J Clin Oncol"},{"key":"4446_CR32","doi-asserted-by":"publisher","first-page":"S1391","DOI":"10.1016\/j.annonc.2025.08.3210","volume":"36","author":"W Xu","year":"2025","unstructured":"Xu W, Choueiri TK, Powles TB, Albiges L, McGregor BA, Andrianova L, et al. 2594MO - association of circulating kidney injury molecule-1 (KIM-1) levels with clinical outcomes in advanced renal cell carcinoma (aRCC): retrospective analysis of COSMIC-313. Ann Oncol. 2025;36:S1391\u20132. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.3210.","journal-title":"Ann Oncol"},{"issue":"5_suppl","key":"4446_CR33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.437","volume":"43","author":"W Xu","year":"2025","unstructured":"Xu W, Vemula SV, Motzer RJ, Chhibber A, Chowbene D, Perrot N, et al. Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): post-hoc analysis of CheckMate 214. J Clin Oncol. 2025;43(5_suppl):437-. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.437.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4446_CR34","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.eururo.2025.05.019","volume":"88","author":"MH Voss","year":"2025","unstructured":"Voss MH, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, et al. First-line Pembrolizumab plus Lenvatinib for advanced non-clear-cell renal cell carcinoma: updated results from the phase 2 KEYNOTE-B61 trial. Eur Urol. 2025;88(6):614\u201324. https:\/\/doi.org\/10.1016\/j.eururo.2025.05.019.","journal-title":"Eur Urol"},{"issue":"16_suppl","key":"4446_CR35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4507","volume":"43","author":"V Narayan","year":"2025","unstructured":"Narayan V, Jonasch E, Iliopoulos O, Maughan BL, Oudard S, Else T, et al. Hypoxia-inducible factor-2\u03b1 (HIF-2\u03b1) inhibitor belzutifan in von Hippel-Lindau (VHL) disease\u2013associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study. J Clin Oncol. 2025;43(16_suppl):4507-. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4507.","journal-title":"J Clin Oncol"},{"issue":"25","key":"4446_CR36","doi-asserted-by":"publisher","first-page":"04953","DOI":"10.1016\/j.annonc.2025.10.009","volume":"S0923\u20137534","author":"AW Hahn","year":"2025","unstructured":"Hahn AW, Chahoud J, Skelton WP, Yuan Y, Zurita AJ, Kovitz C, et al. A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo). Ann Oncol. 2025;S0923\u20137534(25):04953\u201361. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.009.","journal-title":"Ann Oncol"},{"issue":"5","key":"4446_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102402","volume":"23","author":"C Suarez","year":"2025","unstructured":"Suarez C, Reig Torras O, Morales Barrera R, Rodriguez Sanchez A, Anguera Palacios G, Manshino AMB, et al. Effectiveness and safety of Cabozantinib treatment in patients with advanced renal cell carcinoma in Spanish and Portuguese real-world practice: the SOGUG-SPRWEC study. Clin Genitourin Cancer. 2025;23(5):102402. https:\/\/doi.org\/10.1016\/j.clgc.2025.102402.","journal-title":"Clin Genitourin Cancer"},{"issue":"16_suppl","key":"4446_CR38","doi-asserted-by":"publisher","first-page":"4516-","DOI":"10.1016\/j.jncc.2025.03.001","volume":"43","author":"T Zhang","year":"2025","unstructured":"Zhang T, Ballman KV, McGregor BA, Moon H, Matrana MR, Alter RS, et al. Ipilimumab and nivolumab in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated on the phase 3 PDIGREE (Alliance A031704) trial: results from Step 1 analysis. J Clin Oncol. 2025;43(16_suppl):4516-. https:\/\/doi.org\/10.1016\/j.jncc.2025.03.001.","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"4446_CR39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.440","volume":"43","author":"L Albiges","year":"2025","unstructured":"Albiges L, Su\u00e1rez C, Powles T, Motzer RJ, Stadler WM, Miller WH, et al. KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2025;43(5_suppl):440-. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.440.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4446_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2217\/fon-2022-0802","volume":"19","author":"RJ Motzer","year":"2023","unstructured":"Motzer RJ, Schmidinger M, Eto M, Suarez C, Figlin R, Liu Y, et al. LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1\/PD-L1 therapy. Future Oncol. 2023;19(2):113\u201321. https:\/\/doi.org\/10.2217\/fon-2022-0802.","journal-title":"Future Oncol"},{"issue":"5_suppl","key":"4446_CR41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.552","volume":"43","author":"C Su\u00e1rez","year":"2025","unstructured":"Su\u00e1rez C, Albiges L, Beckermann K, Hammers HJ, Stadler WM, Miller WH, et al. KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2025;43(5_suppl):552-. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.552.","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"4446_CR42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.441","volume":"43","author":"TK Choueiri","year":"2025","unstructured":"Choueiri TK, Lee JL, Merchan JR, Patnaik A, Garmezy B, Drakaki A, et al. Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study. J Clin Oncol. 2025;43(5_suppl):441-. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.441.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"4446_CR43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4506","volume":"43","author":"TK Choueiri","year":"2025","unstructured":"Choueiri TK, Ornstein MC, Barata PC, Matrana MR, Merchan JR, Gedye C, et al. Combination Casdatifan plus Cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma. J Clin Oncol. 2025;43(16_suppl):4506-. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4506.","journal-title":"J Clin Oncol"},{"key":"4446_CR44","unstructured":"Coca S, Su\u00e1rez C, Larkin J, Patel P, Valderrama BP, Rodr\u00edguez-Vida A, et al. Randomised phase II trial of durvalumab combinations in advanced clear cell RCC \u2013 final analysis. Presented in the ESMO congress 2025. https:\/\/oncologypro.esmo.org\/congress-resources\/esmo-congress-2025?presentation=final_efficacy_data_and_biomarker_analysis_from_th. Accessed 09 Dec 2025."},{"issue":"16_suppl","key":"4446_CR45","doi-asserted-by":"publisher","first-page":"4598-","DOI":"10.1097\/JU.0000000000004296","volume":"43","author":"SM Prasad","year":"2025","unstructured":"Prasad SM, Mihaylov NV, Khuskivadze A, Genov P, Terzi V, Kates M, et al. Duration of response (DoR) following treatment with UGN-102 in patients with recurrent, low-grade, intermediate-risk, non-muscle invasive, bladder cancer: 18-month DoR data from the phase 3 ENVISION trial. J Clin Oncol. 2025;43(16_suppl):4598-. https:\/\/doi.org\/10.1097\/JU.0000000000004296.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"4446_CR46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4517","volume":"43","author":"T Powles","year":"2025","unstructured":"Powles T, Shore ND, Bedke J, Galsky MD, Palou J, Hu H, et al. Sasanlimab in combination with Bacillus Calmette-Gu\u00e9rin (BCG) in BCG-na\u00efve, high-risk non\u2013muscle-invasive bladder cancer (NMIBC): event-free survival (EFS) subgroup analyses based on disease stage from the CREST study. J Clin Oncol. 2025;43(16_suppl):4517-. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4517.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4446_CR47","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","volume":"31","author":"ND Shore","year":"2025","unstructured":"Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Ku JH, et al. Sasanlimab plus BCG in BCG-na\u00efve, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med. 2025;31(8):2806\u201314. https:\/\/doi.org\/10.1038\/s41591-025-03738-z.","journal-title":"Nat Med"},{"key":"4446_CR48","doi-asserted-by":"crossref","unstructured":"De Santis M, Palou J, Nishiyama H, Krawczynski M, Seyitkuliev A, Novikov A, et al. LBA108 - Durvalumab (D) in combination with Bacillus Calmette-Gu\u00e9rin (BCG) for BCG-na\u00efve, high-risk non-muscle-invasive bladder cancer (NMIBC): final analysis of the phase III, open-label, randomised POTOMAC trial. 2025. https:\/\/cslide.ctimeetingtech.com\/esmo2025\/attendee\/confcal\/presentation\/list?q=durvalumab+combinations. Accesed 09 Dec 2025.","DOI":"10.1016\/j.annonc.2025.09.127"},{"issue":"25","key":"4446_CR49","doi-asserted-by":"publisher","first-page":"04787","DOI":"10.1016\/j.annonc.2025.09.017","volume":"S0923\u20137534","author":"M Roupret","year":"2025","unstructured":"Roupret M, Bertaut A, Pignot G, Neuzillet Y, Houede N, Mathieu R, et al. ALBAN (GETUG-AFU 37): a phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-na\u00efve high-risk, non-muscle invasive bladder cancer (NMIBC). Ann Oncol. 2025;S0923\u20137534(25):04787\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.017.","journal-title":"Ann Oncol"},{"key":"4446_CR50","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001111604.90306.91.04","volume":"213","author":"F Guerrero-Ramos","year":"2025","unstructured":"Guerrero-Ramos F, Jacob JM, van der Heijden MS, B\u00f6gemann M, Daneshmand S, Necchi A, et al. TAR-200 monotherapy in patients with Bacillus Calmette-Gu\u00e9rin\u2013unresponsive papillary disease\u2013only high-risk non\u2013muscle-invasive bladder cancer: first results from cohort 4 of sunRISE-1. J Urol. 2025;213:e2. https:\/\/doi.org\/10.1097\/01.JU.0001111604.90306.91.04.","journal-title":"J Urol"},{"issue":"5_suppl","key":"4446_CR51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.659","volume":"43","author":"MD Galsky","year":"2025","unstructured":"Galsky MD, Heijden MSVD, Catto JWF, Al-Ahmadie H, Meeks JJ, Nishiyama H, et al. Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. J Clin Oncol. 2025;43(5_suppl):659-. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.659.","journal-title":"J Clin Oncol"},{"key":"4446_CR52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.659","author":"JJ Meeks","year":"2025","unstructured":"Meeks JJ, van der Heijden MS, Powles T, Galsky MD, Al-Ahmadie H, Nishiyama H, et al. PD37\u201309. The first report of disease-free survival analyses from the niagara trial of perioperative durvalumab plus neoadjuvant chemotherapy in muscle-invasive bladder cancer. J Urol. 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.659.","journal-title":"J Urol"},{"issue":"16_suppl","key":"4446_CR53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4503","volume":"43","author":"T Powles","year":"2025","unstructured":"Powles T, Heijden MSVD, Wang Y, Catto JWF, Meeks JJ, Al-Ahmadie H, et al. Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative Durvalumab (D) in NIAGARA. J Clin Oncol. 2025;43(16_suppl):4503-. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4503.","journal-title":"J Clin Oncol"},{"key":"4446_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.124","volume":"Suppl2","author":"C Vulsteke","year":"2025","unstructured":"Vulsteke C, Kaimakliotis H, Danchaivijitr P, Sabadash MY, Rodriguez-Vida A, Zhang Z, et al. LBA2 - Perioperative (periop) Enfortumab Vedotin (EV) plus Pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase III KEYNOTE-905 study. Ann Oncol. 2025;Suppl2:S1763. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.124.","journal-title":"Ann Oncol"},{"key":"4446_CR55","doi-asserted-by":"publisher","first-page":"S1767","DOI":"10.1016\/j.annonc.2025.09.131","volume":"36","author":"A Necchi","year":"2025","unstructured":"Necchi A, Guerrero-Ramos F, Crispen PL, Herrera-Imbroda B, Garje R, Szabados BE, et al. LBA112-Neoadjuvant Gemcitabine intravesical system (TAR-200) + Cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC): SunRISe-4 (SR-4) primary analysis and biomarker results. Ann Oncol. 2025;36:S1767\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.131.","journal-title":"Ann Oncol"},{"issue":"10","key":"4446_CR56","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S1470-2045(25)00358-4","volume":"26","author":"A Necchi","year":"2025","unstructured":"Necchi A, Guerrero-Ramos F, Crispen PL, Herrera-Imbroda B, Garje R, Powles T, et al. TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial. Lancet Oncol. 2025;26(10):1312\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(25)00358-4.","journal-title":"Lancet Oncol"},{"key":"4446_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.109","volume":"36","author":"TB Powles","year":"2025","unstructured":"Powles TB, Kann A, Castellano-Gauna DE, Goupil MG, Nishiyama H, Bracarda S, et al. LBA8 - IMvigor011: a phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer. Ann Oncol. 2025;36:S1749. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.109.","journal-title":"Ann Oncol"},{"issue":"5_suppl","key":"4446_CR58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.664","volume":"43","author":"T Powles","year":"2025","unstructured":"Powles T, Heijden MSVD, Loriot Y, Bedke J, Valderrama BP, Iyer G, et al. EV-302: updated analysis from the phase 3 global study of Enfortumab Vedotin in combination with Pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la\/mUC). J Clin Oncol. 2025;43(5_suppl):664-. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.664.","journal-title":"J Clin Oncol"},{"key":"4446_CR59","doi-asserted-by":"crossref","unstructured":"Gupta S, Bedke J, Van der Heijden MS, P\u00e9rez-Valderrama B, Kikuchi E, Hoffman-Censits J, et al. Exploratory analysis of responders from the phase 3 EV-302 trial of enfortumab vedotin plus pembrolizumab vs. chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. Presented at the ASCO GU congress 2025. https:\/\/www.asco.org\/meetings-education\/meetings\/meeting-slides-videos. Accesed 09 Dec 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.4502"},{"issue":"9","key":"4446_CR60","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.annonc.2025.05.010","volume":"36","author":"J Hoffman-Censits","year":"2025","unstructured":"Hoffman-Censits J, Tsiatas M, Chang PM, Kim M, Antonuzzo L, Shin SJ, et al. Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis. Ann Oncol. 2025;36(9):1088\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.010.","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"4446_CR61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4500","volume":"43","author":"MSVD Heijden","year":"2025","unstructured":"Heijden MSVD, Galsky MD, Powles T, Necchi A, Ye D, Zhang P, et al. Nivolumab plus Ipilimumab (NIVO+IPI) vs Gemcitabine-Carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): final results for cisplatin-ineligible patients from the CheckMate 901 trial. J Clin Oncol. 2025;43(16_suppl):4500-. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4500.","journal-title":"J Clin Oncol"},{"key":"4446_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.125","volume":"36","author":"J Guo","year":"2025","unstructured":"Guo J, Sheng X, Zeng G, Zhang C, Zhang Q, Bian J, et al. LBA7 - Disitamab vedotin (DV) plus toripalimab (T) versus chemotherapy (C) in first-line (1L) locally advanced or metastatic urothelial carcinoma (la\/mUC) with HER2-expression. Ann Oncol. 2025;36:S1764. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.125.","journal-title":"Ann Oncol"},{"key":"4446_CR63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511648","author":"X Sheng","year":"2025","unstructured":"Sheng X, Zeng G, Zhang C, Zhang Q, Bian J, Niu H, et al. Disitamab Vedotin plus Toripalimab in HER2-expressing advanced urothelial cancer. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2511648.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04446-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04446-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04446-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:02:05Z","timestamp":1792803725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04446-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":63,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["4446"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04446-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Carlos \u00c1lvarez-Fern\u00e1ndez reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Merck, Pfizer, Astra-Zeneca, and Bayer; and support for attending meetings and\/or travel from Ipsen, Roche, and Pfizer. Urbano Anido- Herranz reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Merck, Ipsen, MSD, Roche, Astra-Zeneca, Janssen, Bayer, BMS and Novartis; support for attending meetings and\/or travel from MSD, Ipsen, Novartis, Roche, Rovi and BMS; and having participated in Advisory Board for Pfizer. Cristina Azpitarte Raposeiras reports having received honoraria for presentations, speakers\u00b4 bureaus from BMS, Merck, Takeda, Janssen, AstraZeneca, Roche, Lilly, Bayer, MSD and Ipsen; support for attending meetings and\/or travel from Roche, MSD, Lilly, Ipsen, AstraZeneca, Takeda and Bayer. Javier Casas-Nebra reports having received consulting fees, payment or honoraria for presentations, speakers or educational events from Astellas, Johnson&Johnson, Bayer; support for attending meetings and\/or travel from Bayer, Johnson & Johnson; and having participated in an Advisory Board for AstraZeneca\u00a0and Pfizer. Emilio Esteban-Gonz\u00e1lez reports financial support to participate, travel, and attend the 2024 Cambados annual meeting. Ovidio Fern\u00e1ndez Calvo reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Astellas, Bayer Bristol-Myers Squibb, Ipsen, Novartis and Roche; support for attending meetings and\/or travel from Astellas, Bristol-Myers Squibb and Ipsen; and having participated in a Data Safety Monitoring Board or Advisory Board for Astellas, Bristol- Myers Squibb, Eisai, Merck, and Pfizer. Natalia Fern\u00e1ndez N\u00fa\u00f1ez reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Pfizer, Ipsen, Roche, BMS, Bayer, Astra-Z\u00e9neca, MSD, and Lilly; support for attending meetings and\/or travel from Pfizer, Ipsen, Roche, BMS, Bayer, Astra Z.neca, MSD, and Lilly; and having participated in a Data Safety Monitoring Board or Advisory Board for Pfizer. Alicia Folgar-Torres reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Johnson &Johnson, Ipsen; support for attending meetings and\/or travel from Astellas, Janssen, Kyowa Kirin and GP-Pharm. Enrique Gallardo reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Astellas, Janssen, Sanofi, Bayer, Ipsen, Pfizer, Roche, BMS, MSD, Rovi, Daiichi Sankyo, Leo Pharma, Eisai, Boehringer Ingelheim, Merck, Recordati, Lilly, Advanced Accelerator Applications and GSK; support for attending meetings and\/or travel from Astellas, AstraZeneca, Bayer, BMS, Eisai, Ipsen, Janssen, Leo Pharma, Pfizer, Roche, Recordati and MSD.; and having participated in a Data Safety Monitoring Board or Advisory Board forJanssen, Astellas, Bayer, Ipsen, Pfizer, Roche, Eisai, Recordati, BMS, MSD, AstraZeneca, Merck, Lilly, GSK, Advanced Accelerator Applications. Carme Garc\u00eda Lorenzo reports having received payment or honoraria for speaker, travel, or accommodation for attending meetings from Merck, Ipsen, Bayer, Astellas, BMS, MSD, Janssen. Ar\u00e1nzazu Gonz\u00e1lez del Alba has received research funding from AstraZeneca, travel grants from AstraZeneca, Bayer, Recordati, Ipsen, Merck, MSD and Roche, and honoraria for speaker engagements, advisory boards, medical writing and continuous medical education from Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, BMS, Casen Recordati, Eisai, EUSA Pharma, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer Roche and Veracyte. Mart\u00edn L\u00e1zaro-Quintela reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Merck, Ipsen, MSD, Lilly, Roche, Astra-Zeneca, Janssen, Regeneron, Bayer, BMS and Novartis; support for attending meetings and\/or travel from MSD, Ipsen, Takeda, Roche and BMS; and having participated in a Data Safety Monitoring Board or Advisory Board for Pfizer, Merck, Astellas, Bayer, Telix, BMS and Novartis. David Lorente reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Janssen, Astellas, Pfizer, Bayer, BMS and Astra Zeneca; and support for attending meetings and\/or travel from Janssen, Astellas, Bayer and Pfizer. Mar\u00eda Jos\u00e9 M\u00e9ndez-Vidal reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Merck, Ipsen, MSD, Astra-Zeneca, Janssen, Bayer, BMS and Novartis; support for attending meetings and\/or travel from, Ipsen, Jassen, Recordati Rare Diseases and BMS; and having participated in an Advisory Board for Ipsen, Astra Zeneca, Janssen, Pfizer, Astellas, Telix, BMS and Novartis. Aurea Molina D\u00edaz reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Merck, Ipsen, Eisai, Gr\u00fcnenthal Pharma, Kyowa Kirirn, Phamamar, BMS and Roche; support for attending meetings and\/or travel from Pfizer, BMS, MSD, Eisai, Kyowa Kirirn, Mark, Pharmamar, AstraZeneca, Lilly, Sanofi, Takeda, Astellas, Roche, Pierre Fabre and Servier; and having participated in Advisory Board for Bayer, Pfizer, BMS, MSD, Eisai, Pierre Fabre, Pharmamar, Pfizer, Merck, Astellas, Recordati, deciphera and Novocure. Ignacio Pel\u00e1ez Fern\u00e1ndez reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Astellas, Bayer, Merck, Ipsen. BMS, Roche, Pfizer, Astra Zeneca and Novartis. Support for attending meetings and\/or travel from, Ipsen, Pfizer and Merck; and having participated in an Advisory Board for Ipsen, Astra Zeneca, Pfizer and Astellas. Daniel P\u00e9rez-Fentes reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Astellas, Johnson &Johnson, Bayer, Accord; support for attending meetings and\/or travel from Bayer, Johnson & Johnson; and having participated in a Data Safety Monitoring Board or Advisory Board for Astellas, Bayer, Johnson & Johnson and Recordati. Ignacio Rodr\u00edguez reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events from Astellas, Johnson & Johnson, Bayer and Sanofi; and having participated in Advisory Board for Astellas, Bayer, Johnson & Johnson and GSK. Cristina Su\u00e1rez reports having received research funding from BMS, Pfizer, Roche and Ipsen, consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events from Ipsen, EISAI, MSD; support for attending meetings and\/or travel from Ipsen, MSD, Bayer, and having participated in Advisory Board for BMS, Pfizer, IPSEN, MSD, EUSA Ph and Tellix. Bego\u00f1a P. Valderrama reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus or educational events from Astellas Pharma, Roche, Novartis AAA, Astra-Zeneca, Bayer, Bristol-Myers-Squibb, Merck, MSD, Pfizer, Ipsen, Janssen and Almirall Pharma; and support for attending meetings and\/or travel from Bristol-Myers-Squibb, Pfizer, Roche, Astellas Pharma, MSD, Merck and Astra-Zeneca. Sergio V\u00e1zquez Est\u00e9vez reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Merck, Ipsen, MSD, Astra-Zeneca, Janssen, Bayer, BMS and Novartis; support for attending meetings and\/or travel from, Ipsen, Bayer and Roche; and having participated in an Advisory Board for Ipsen, Astra Zeneca, Janssen, Pfizer, Astellas, BMS, Bayer and Novartis.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Human and animal rights","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}